A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Clinical trial NCT06361888 · RECRUITING
Trial details
- NCT number
- NCT06361888
- Sponsor
- Hutchmed
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-08
- Primary completion
- 2028-05-31
- Enrollment
- 502
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.